We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Highly Multiplexed Cell Surface Protein Analyzed Via Flow Cytometry

By LabMedica International staff writers
Posted on 06 Oct 2021
Print article
Image: The BD LSRFortessa X-20 Cell Analyzer can be configured with up to five lasers to detect up to 20 parameters simultaneously to support ever increasing demands in multicolor flow cytometry (Photo courtesy of BD Biosciences)
Image: The BD LSRFortessa X-20 Cell Analyzer can be configured with up to five lasers to detect up to 20 parameters simultaneously to support ever increasing demands in multicolor flow cytometry (Photo courtesy of BD Biosciences)
Modern immunologic studies increasingly requires high-dimensional analyses to understand the complex milieu of cell types that comprise the tissue microenvironments of disease. One of the cornerstones of immunology has been the detailed phenotypic classification of the cellular populations of the immune system.

Modern flow cytometric approaches exemplify this by using panels of multiple fluorochrome-conjugated (conventional flow cytometry) or metal-conjugated (mass cytometry) antibodies to measure protein expression profiles of individual cells with high cell throughput to capture and analyze both common and rare cell populations.

Clinical Scientists at the Fred Hutchinson Cancer Institute (Seattle, WA, USA) developed a workflow that enables highly multiplexed analysis of cell surface proteins using conventional flow cytometry. The method uses machine learning combined with data from overlapping flow cytometry assay panels to determine the co-expression patterns of hundreds of cell surface markers across millions of single cells.

The approach, named Infinity Flow, uses traditional flow cytometry as opposed to newer technologies like mass cytometry; it offers a potentially more accessible and less expensive route for single-cell proteomic studies. The method consists of two steps. First, the scientists stain all the cells in an experiment with antibodies to a small number of proteins. This is called the "backbone" panel and typically consists of around the 20 analytes that can be multiplexed using a conventional flow cytometer.

The scientists then subdivide the sample into a series of wells, each containing one of the additional antibodies to the proteins they are interested in. For instance, if the investigator want to look at another 200 proteins beyond those covered in the backbone panel, they would subdivide their sample into 200 different wells, each of which would contain an antibody against one of those 200 proteins. They then analyze each well of samples using flow cytometry, the BD Fortessa X-20 cytometer (BD Biosciences, Franklin Lakes, NJ, USA) allowing them to collect for each cell expression data on all of the "backbone" proteins along with data on the one additional protein designated for that sample well. With this data, the Infinity Flow software is able to predict for every cell being analyzed the expression levels of the 200 proteins of interest.

The team found that when they used a backbone panel of proteins common to all T cells, they were unable to impute protein expression levels for particular T-cell types due to the fact that, based on the backbone signature, all T cells looked the same. This, they noted, indicates that tailoring backbone panels to the samples and cell populations of interest can improve the assay's performance. They also found that the method was best able to impute expression levels for proteins that exhibited multimodal expression patterns and were highly or commonly expressed. In an evaluation of an Infinity Flow assay detailed in the study, they determined that they were able to generate "meaningful imputed signal" for 155 of 252 markers measured.

Mark Headley, PhD, an assistant professor in immunology and a leading author of the study, said, “Infinity Flow costs scale more slowly. We can measure 10 million, 20 million, 30 million cells at the same cost. It doesn't cost you more to do the assay the more cells you do.” The study was published on September 22, 2021 in the journal Science Advances.

Related Links:
Fred Hutchinson Cancer Institute
BD Biosciences



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The cobas Malaria test is the first FDA-approved molecular test to screen U.S. blood donors for malaria (Photo courtesy of Roche)

First FDA-Approved Molecular Test to Screen Blood Donors for Malaria Could Improve Patient Safety

Malaria, a serious illness that often leads to death, is spread by a specific mosquito species that infect humans with a parasite. Other transmission modes include blood transfusions, organ transplants,... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The medical office procedure detects the key biomarker in Parkinson’s and related neurodegenerative diseases (Photo courtesy of BIDMC)

Simple Skin Biopsy Test Detects Parkinson’s and Related Neurodegenerative Diseases

Parkinson's disease and a group of related neurodegenerative disorders known as synucleinopathies impact millions globally. These conditions, including Parkinson’s disease (PD), dementia with Lewy bodies... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.